<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4CA2F3E4-5AB4-4F33-B4D5-985874BBE294"><gtr:id>4CA2F3E4-5AB4-4F33-B4D5-985874BBE294</gtr:id><gtr:firstName>Lorraine M.</gtr:firstName><gtr:surname>Work</gtr:surname><gtr:orcidId>0000-0002-6462-4109</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1100562"><gtr:id>28B52CB8-E3C0-459F-A86E-56880974D357</gtr:id><gtr:title>Modulation of microRNA as a therapeutic strategy for stroke</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100562</gtr:grantReference><gtr:abstractText>Stroke is the 3rd leading cause of death in the UK and the leading cause of longterm disability. With a growing elderly population the socioeconomic burden attributed to stroke is going to continue to increase in coming years. There is currently only one clinically approved treatment for stroke and due to tight safety constraints only 5% of sufferers receive this intervention. Clearly, there is a pressing and urgent need to identify novel intervention strategies and better define the mechanisms of stroke lesion progression and accompanying neurological deficit. microRNAs (miRNAs) are small molecules which can alter the expression of many targets involved in the divergent and converging pathways implicated in stroke lesion progression. By manipulating the expression of these miRNAs I postulate that improvments in outcome following stroke can be achieved. Uniquely, by altering the expression of one single miRNA effects on many pathways involved in disease progression can be achieved. This polytherapy approach has been shown to be successful for the management of diseases such as high blood pressure through multi-drug prescribing. To improve the clinical translation of our studies we will study these effects in an animal model which reflects many of the risk factors those likely to suffer a stroke have (e.g. high blood pressure, altered metabolic handling) and look to alter miRNA expression in the days following experimental stroke - a time window which would be attractive from a clinical standpoint. Alteration of miRNA will be achieved using novel gene delivery sytems based on a non-replicating virus which has been shown to efficiently target neurons in the brain. This virus is safe and doesn t cause an immune response in humans (unlike some gene delivery vectors). Together, the approach outlined here will help define the validity of gene delivery to alter miRNA expression in a robust experimental model of stroke and so could have important implications for future intervention strategies in the clinic.</gtr:abstractText><gtr:technicalSummary>This project aims to determine the effect of microRNA (miRNA) modulation as a novel intervention strategy in a robust pre-clinical model of stroke. Given that one miRNA can alter the expression of many both divergent and converging genes in multiple pathways, through a single modulation a significant effect on those pathways implicated in lesion progression or the promotion of endogenous repair will be achieved. Initially, the expression of miRNA which have been previously published to be altered following cerebral ischaemia will be validated in our experimental model of transient middle cerebral artery occlusion (tMCAO) in the spontaneously hypertensive stroke prone rat (SHRSP) and an in vitro model of hypoxia/reoxygenation. The in vitro model will allow the effect of specific miRNA modulation by lentivirus infection (over-expression or knockdown) to be determined through a number of functional assays prior to translation to the in vivo model. On identification of the most promising therapeutic miRNA candidates for modulation from the in vitro characterisation studies a canine adenovirus-2 (CAV-2) vector will be generated. CAV-2 has been shown to be highly neurotrophic in the SHRSP and other animal models of neurodegenerative diseases. Its marked efficiency of neuronal transduction, retrograde transport from the injection site resulting in a significant area of transduction and lack of immune response due to a lack of existing immunity make it an ideal and novel vector for study in the current proposal. CAV-2 will be administered by stereotaxic injection 24 hours post-tMCAO in the SHRSP and the effect of miRNA modulation (up to 4 therapeutic groups vs control tMCAO and sham controls) determined. To fully characterise the effect of such intervention animals will be taken out to 21 days post-tMCAO to monitor neurological recovery (using the tapered beam test and assessment of neurological score through a battery of 10 tests), infarct volume (by H&amp;amp;E staining) and functional assays (IHC for specific proteins, western blotting, biochemical assays, pressure myography). This will provide a comprehensive follow-up to ascertain the effect of specific miRNA in the setting of experimental stroke. Through the studies outlined here, I aim to demonstrate the therapeutic potential of miRNAs for stroke using a novel gene delivery vector in a robust and clinically relevant experimental model at a timepoint which would be clinically significant.</gtr:technicalSummary><gtr:fund><gtr:end>2016-02-29</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>398738</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mitochondrial Biology Unit</gtr:department><gtr:description>MitoQ</gtr:description><gtr:id>33C852AC-996B-4FD2-B058-25030ACC794B</gtr:id><gtr:impact>It is likely that an abstract will be submitted to the XXVIth meeting of the ISCBFM in Shanghai, May 2013. In addition, a full scientific publication should result in 2013 on completion of the study. We plan to submit a collaborative grant application early in 2013 based on strong pilot data generated in vitro and in vivo.</gtr:impact><gtr:partnerContribution>In addition to providing the compounds for us to use they have contributed to experimental design and advised on matters arising from the in vivo studies.</gtr:partnerContribution><gtr:piContribution>Having been given 2 novel mitochondrial targeted compounds my research team are determining their efficacy in a pertinent preclinical model of stroke using hypertensive rats. We are nearing completion of one large in vivo study and generating novel pilot data to form the basis of a new collaborative project grant application</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Mitochondrial Biology Unit</gtr:department><gtr:description>Mitochondrial Therapies Group</gtr:description><gtr:id>3E157EA1-EE29-48DC-BAF3-10DB7CCC67C4</gtr:id><gtr:impact>To facilitate collaboration we have started to assemble a collaboration agreement between the University of Cambridge, MRC and the University of Glasgow. The aim is to simplify the interaction so that we can have free exchange of reagents and ideas between all parties. In addition, this will mean that external grant application requirements will be satisfied by this collaboration agreement.</gtr:impact><gtr:partnerContribution>The MTG is being led by colleagues and collaborators in Cambridge. They have the expertise in mitochondrial biology and are developing new compounds all the time with a view to targeting agents/compounds to the mitochondria (in collaboration with the School of Chemistry at the University of Glasgow and others).</gtr:partnerContribution><gtr:piContribution>The Mitochondrial Therapies Group (MTG) aims to develop novel therapies to treat the mitochondrial dysfunction that contributes to common pathologies that affect our ageing populations. Many of these disorders are not usually thought of as &amp;quot;mitochondrial&amp;quot; and include ischaemia-reperfusion injury in heart attack, organ preservation for transplantation and stroke as well as diabetes, metabolic syndrome and inflammatory disorders. My research group provides expertise (intellectual and technical) relating to stroke.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>School visit (Glasgow)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>293A4315-6CC8-470D-A3A5-65F8DD7FFB20</gtr:id><gtr:impact>Students asked lots of questions and there was a lot of discussion with each group.

The teacher involved reported excellent feedback from the students about the visit.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School careers fair</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>86C3F335-92F4-40D3-94DB-EB0371F08F4F</gtr:id><gtr:impact>Routes into employment (Speed networking event) for senior year group. There was considerable discussion and interest in terms of career progression from school to university and then beyond to PhD level. Clearly, understanding of requirements to establish an independent research group were beyond their appreciation of the career path after postgraduate studies but they were interested to hear about ongoing research areas.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Glasgow)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7B10BC95-2124-4D6B-A36B-A8836B8F6554</gtr:id><gtr:impact>Lots of questions and discussion both from the students and also teachers.

Session was in Oct and so too early to report back although feedback on the day was very positive.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>STEM &quot;Lab in a lorry&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>588FAF36-6B2E-4A27-86D2-3A70A7F5702B</gtr:id><gtr:impact>90-110 pupils attended the session each day with it running over 3 days (only directly involved in one of these days).

The event was a great success and will run again at the same school (and others) next year.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Glasgow)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>5D4C714D-415D-486A-9EED-6D47B370ECAD</gtr:id><gtr:impact>Over 200 pupils and their families attended the evening science fair covering a wide range of areas. Many came to discuss the brain and consequences of neurological disease and enthusiastically took part in the activities set up.

STEM reported that the event was a tremendous success receiving excellent feedback from those who left it.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Larbert)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>9C38EBA6-358A-4A43-9D13-EEA3E10CF0D1</gtr:id><gtr:impact>A session was held covering career progression and career options for 20 advanced higher biology students relating to science.

This was the 2nd time such a session had been delivered and the school is keen to maintain contact and continue to run another 2 sessions covering different topics over the course of the year.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>7DAA8135-1091-4A95-9EBD-0797ECEF6347</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>86103</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:id>C7AE103E-ED99-46B4-9BCB-441DB6638C13</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15795</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ISSF Short-term support</gtr:description><gtr:end>2014-04-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>B1E95384-F0E3-49C1-9B77-1C41D7C9B382</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>78864</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K500847/1</gtr:fundingRef><gtr:id>F9996937-C1B0-40DB-BEDC-00055490CE2D</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>85000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>6EDC0F90-FAA9-40C9-A856-80ED331F0842</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>British Heart Foundation (BHF)</gtr:fundingOrg><gtr:id>0A9E9241-FE1D-43E9-9848-54E035F9BFDA</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>83000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>The Cunningham Trust</gtr:department><gtr:description>PhD studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>University of St Andrews</gtr:fundingOrg><gtr:id>7F454005-007B-495C-9260-605B51203462</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>192739</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research grant</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>The Henry Smith Charity</gtr:fundingOrg><gtr:id>F02EEBC0-0729-4AAF-B2F9-83CDAB9CB1D0</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24858</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strategic skills award</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K500847/1</gtr:fundingRef><gtr:id>2FAD08A9-258E-47E4-8044-BBD88FA18E38</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>29981</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Research grant</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>American College of Laboratory Animal Medicine (ACLAM)</gtr:fundingOrg><gtr:id>9FC9B04F-2575-4B00-AD89-3B8607D6187E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>The Work research group (University of Glasgow) has been involved with the Murphy group at Cambridge in the assessment of new compound to inhibit succinate dehydrogenase, as a possible treatment for ischaemia-reperfusion injuries that occur when blood flow to an organ is stopped and then restarted, for example stroke or heart attack.</gtr:description><gtr:id>1EC8FA02-DC72-4235-8BF6-99F3F784AFB0</gtr:id><gtr:impact>This covers assignment of Glasgow IP rights in UK priority Patent application &amp;quot;Succinate dehydrogenase inhibitors&amp;quot; filed at the UK Patent Office on the (UK 1411937.4) to the MRC.</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:patentId>PCT/GB2015/051949</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Succinate Dehydrogenase Inhibitors</gtr:title><gtr:yearProtectionGranted>2015</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have received grant funding from ACLAM ($29,981) to determine whether an enhanced care package favourably alters welfare measures in rats after experimental stroke.</gtr:description><gtr:id>43324538-A3AF-435D-84B5-6493DDA1612F</gtr:id><gtr:impact>The work on this project will begin in April 2016 with anticipated impact expected a year after on publication of the results.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Welfare study for pre- and post-operative care</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/589B7195-ED5F-4D8A-9B0B-BC0CC074BA3B"><gtr:id>589B7195-ED5F-4D8A-9B0B-BC0CC074BA3B</gtr:id><gtr:title>miRNA Profiling and Modulation Following Ischaemic Stroke</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d422ab14ec270ce91a65360025b76f92"><gtr:id>d422ab14ec270ce91a65360025b76f92</gtr:id><gtr:otherNames>Ord, ENJ</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A8020822-E630-4C4B-ABAB-F3D7A7046E31"><gtr:id>A8020822-E630-4C4B-ABAB-F3D7A7046E31</gtr:id><gtr:title>Exosomal miRNA Profiling Following Ischaemic Stroke: clinical and pre-clinical data</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11070d33e26174e2708777af2e5a0ed4"><gtr:id>11070d33e26174e2708777af2e5a0ed4</gtr:id><gtr:otherNames>van Kralingen, JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8F939C83-F242-4E22-82D8-1EA340000153"><gtr:id>8F939C83-F242-4E22-82D8-1EA340000153</gtr:id><gtr:title>Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b194fb2b4c2aca6f8612ef5f9eb99990"><gtr:id>b194fb2b4c2aca6f8612ef5f9eb99990</gtr:id><gtr:otherNames>Chouchani ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E765C71-743F-4081-9030-9D8ED90C7C6D"><gtr:id>1E765C71-743F-4081-9030-9D8ED90C7C6D</gtr:id><gtr:title>Human serum microRNA profiles after ischaemic stroke</gtr:title><gtr:parentPublicationTitle>CEREBROVASCULAR DISEASES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6433906106af99de2c24f76633cbf943"><gtr:id>6433906106af99de2c24f76633cbf943</gtr:id><gtr:otherNames>Breen C. R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9AAFA6BC-33D9-495C-BAFC-5153DB696BC6"><gtr:id>9AAFA6BC-33D9-495C-BAFC-5153DB696BC6</gtr:id><gtr:title>miRNA profiling of the evolving and final peri-infarct tissue in the SHRSP</gtr:title><gtr:parentPublicationTitle>UK Preclinical Stroke Symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d471d11ce65ee5bab9aeeae23c1a8a0"><gtr:id>4d471d11ce65ee5bab9aeeae23c1a8a0</gtr:id><gtr:otherNames>Ord, Emily N.J.</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2BF045DC-B936-48B6-AED0-9D0D8F5D4F64"><gtr:id>2BF045DC-B936-48B6-AED0-9D0D8F5D4F64</gtr:id><gtr:title>A Unifying Mechanism for Mitochondrial Superoxide Production during Ischemia-Reperfusion Injury.</gtr:title><gtr:parentPublicationTitle>Cell metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b194fb2b4c2aca6f8612ef5f9eb99990"><gtr:id>b194fb2b4c2aca6f8612ef5f9eb99990</gtr:id><gtr:otherNames>Chouchani ET</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1550-4131</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6CAFA64D-5067-4322-A048-0A99FB276E2A"><gtr:id>6CAFA64D-5067-4322-A048-0A99FB276E2A</gtr:id><gtr:title>Determination of serum microRNA profiles in human stroke patients</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11070d33e26174e2708777af2e5a0ed4"><gtr:id>11070d33e26174e2708777af2e5a0ed4</gtr:id><gtr:otherNames>van Kralingen, JC</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/23A71372-0556-40F8-A070-E099DF42BCBB"><gtr:id>23A71372-0556-40F8-A070-E099DF42BCBB</gtr:id><gtr:title>Determination of microRNA profiles in extracellular vesicles isolated from serum of human stroke patients</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/11070d33e26174e2708777af2e5a0ed4"><gtr:id>11070d33e26174e2708777af2e5a0ed4</gtr:id><gtr:otherNames>van Kralingen, JC</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0349B9DA-C316-43A6-B620-1B2280291F55"><gtr:id>0349B9DA-C316-43A6-B620-1B2280291F55</gtr:id><gtr:title>Human serum microRNA profiles after ischaemic stroke</gtr:title><gtr:parentPublicationTitle>CEREBROVASCULAR DISEASES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6433906106af99de2c24f76633cbf943"><gtr:id>6433906106af99de2c24f76633cbf943</gtr:id><gtr:otherNames>Breen C. R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B25C0B11-7AE5-4B89-A51B-0E0ED7C2781E"><gtr:id>B25C0B11-7AE5-4B89-A51B-0E0ED7C2781E</gtr:id><gtr:title>Oxidative Stress and the Use of Antioxidants in Stroke.</gtr:title><gtr:parentPublicationTitle>Antioxidants (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f57a550768e7053a69da5f8d0c2b5b7d"><gtr:id>f57a550768e7053a69da5f8d0c2b5b7d</gtr:id><gtr:otherNames>Shirley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2076-3921</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5B6474B8-D2AE-4366-BF1D-79C4A4F6CC7B"><gtr:id>5B6474B8-D2AE-4366-BF1D-79C4A4F6CC7B</gtr:id><gtr:title>miR-494 Modulation as a therapeutic target in experimental stroke</gtr:title><gtr:parentPublicationTitle>UK Preclinical Stroke Symposium</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d091e2737809f346b91a5c6ca93d927b"><gtr:id>d091e2737809f346b91a5c6ca93d927b</gtr:id><gtr:otherNames>van Kralingen, Josie C.</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1C26789E-F6B4-4239-93D5-AFF928F51D88"><gtr:id>1C26789E-F6B4-4239-93D5-AFF928F51D88</gtr:id><gtr:title>miRNA profiling of the ischaemic penumbra</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d422ab14ec270ce91a65360025b76f92"><gtr:id>d422ab14ec270ce91a65360025b76f92</gtr:id><gtr:otherNames>Ord, ENJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FCFA821E-54C6-49C8-AF95-2B20DBC1D644"><gtr:id>FCFA821E-54C6-49C8-AF95-2B20DBC1D644</gtr:id><gtr:title>miRNA profiling of hypoxia-induced neuronal and glial cell-derived exosomes</gtr:title><gtr:parentPublicationTitle>Not published</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/202706ca16333d4720180d8acbecb840"><gtr:id>202706ca16333d4720180d8acbecb840</gtr:id><gtr:otherNames>Ord, E.N.J.</gtr:otherNames></gtr:author></gtr:authors></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BEDA5692-D605-4515-A02E-627A8850771F"><gtr:id>BEDA5692-D605-4515-A02E-627A8850771F</gtr:id><gtr:title>Human serum microRNA profiles after ischaemic stroke</gtr:title><gtr:parentPublicationTitle>CEREBROVASCULAR DISEASES</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6433906106af99de2c24f76633cbf943"><gtr:id>6433906106af99de2c24f76633cbf943</gtr:id><gtr:otherNames>Breen C. R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1015-9770</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100562</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>